Last $97.81 USD
Change Today +0.005 / 0.01%
Volume 1.7M
As of 3:00 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

cubist pharmaceuticals inc (CBST) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/8/14 - $101.03
52 Week Low
07/23/14 - $58.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

cubist pharmaceuticals inc (CBST) Related Businessweek News

View More BusinessWeek News

cubist pharmaceuticals inc (CBST) Details

Cubist Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. The company offers CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; DIFICID for the treatment of clostridium difficile-associated diarrhea (CDAD); and ENTEREG (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. It also develops Tedizolid Phosphate, a novel antibiotic product candidate for the treatment of serious gram-positive bacterial infections; and Ceftolozane/tazobactam, an I.V. antibacterial product candidate for the treatment of certain serious gram-negative bacterial infections in the hospital. In addition, the company develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; and Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain. Cubist Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Lexington, Massachusetts.

873 Employees
Last Reported Date: 02/25/14
Founded in 1992

cubist pharmaceuticals inc (CBST) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $750.0K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $358.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $475.0K
Senior Vice President and General Manager of ...
Total Annual Compensation: $440.2K
Compensation as of Fiscal Year 2013.

cubist pharmaceuticals inc (CBST) Key Developments

Cubist Pharmaceuticals Seeks Acquisitions

Cubist Pharmaceuticals Inc. (NasdaqGS:CBST) is looking for acquisition opportunities. The firm's investigation seeks to determine, among other things, whether the Company's Board of Directors failed to satisfy their duties to shareholders, including whether the Board adequately pursued alternatives to the acquisition and whether the Board obtained the best price possible for the Company’s shares of common stock.

Cubist Pharmaceuticals Seeks Acquisitions

Cubist Pharmaceuticals Inc. (NasdaqGS:CBST) is seeking acquisitions. Michael Tomsicek, Chief Financial Officer of Cubist Pharmaceuticals,s aid, "We have the cash on hand and the financial means for appropriate drugs to add to the portfolio. Where we have something to say either in development or in the commercialization of the drug, we will remain active."

Cubist Pharmaceuticals Inc. Announces Executive Changes

Cubist Pharmaceuticals reported that Patrick Vink, M.D., M.B.A., currently Senior Vice President and General Manager of Cubist's International Business, has been promoted to Executive Vice President and Chief Operating Officer, effective January 1. In his new role, Dr. Vink will oversee all global commercial, manufacturing, technical operations, international business operations, and alliance management. Dr. Vink will report into Robert J. Perez, Cubist's current President and COO who, as reported on October 20, will become the company's Chief Executive Officer effective January 1, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBST:US $97.81 USD +0.005

CBST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €13.16 EUR +0.33
Nektar Therapeutics $15.66 USD +0.455
Salix Pharmaceuticals Ltd $116.21 USD +1.72
Shionogi & Co Ltd ¥3,175 JPY +135.00
Synergy Health PLC 2,067 GBp +55.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CBST Industry Range
Price/Earnings 100.0x
Price/Sales 6.3x
Price/Book 4.8x
Price/Cash Flow 112.9x
TEV/Sales 5.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUBIST PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at